Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials

Case Report: Carfilzomib-induced Thrombotic Microangiopathy With Complement Activation Treated Successfully With Eculizumab

(2020) Divaya Bhutani et al.   Clinical Lymphoma Myeloma & Leukemia

Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible, NDMM patients

(2019) Thierry Facon et al.   BLOOD

Monoclonal gammopathy‐associated thrombotic microangiopathy

(2019) Jennifer C. Yui et al.   AMERICAN JOURNAL OF HEMATOLOGY

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

(2019) Ola Landgren et al.   LEUKEMIA

Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma

(2019) Robert F. Cornell et al.   JOURNAL OF CLINICAL ONCOLOGY

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

(2018) Philippe Moreau et al.   LANCET ONCOLOGY

Carfilzomib-Associated Cardiovascular Adverse Events

(2018) Adam J. Waxman et al.   JAMA Oncology

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

(2017) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies

(2017) Weijuan Li et al.   JAMA Oncology

Proteasome inhibitor associated thrombotic microangiopathy

(2016) Jennifer C. Yui et al.   AMERICAN JOURNAL OF HEMATOLOGY

Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma

(2016) Rimda Wanchoo et al.   Clinical Journal of the American Society of Nephrology

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

(2016) R Hájek et al.   LEUKEMIA

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

(2016) A Rosenthal et al.   Blood Cancer Journal

Meta-analysis in clinical trials revisited

(2015) Rebecca DerSimonian et al.   Contemporary Clinical Trials

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib-Associated Tumor Lysis Syndrome

(2014) Ryan N. Shely et al.   PHARMACOTHERAPY

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2013) Alessandro Liberati   ANNALS OF INTERNAL MEDICINE

Kidney Disease and Multiple Myeloma

(2013) E. C. Heher et al.   Clinical Journal of the American Society of Nephrology

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

(2013) A Z Badros et al.   LEUKEMIA

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD